Supriya Lifescience Eyes Revenue Surge with Strategic Expansion

Supriya Lifescience aims to reach Rs 1,600 crore in revenue from facility expansions over the next three years. The active pharmaceutical ingredient company targets new markets and products while increasing research investment. Export-driven, it plans to enhance its niche supplier role amidst global industry volatility.

Supriya Lifescience is setting ambitious growth targets, aiming for up to Rs 1,600 crore in revenue in the next three years from its Lote MIDC and Ambernath facilities, according to Managing Director Saloni Wagh.

The company had Rs 706 crore in revenue in 2024-25, projecting a 20% growth in FY26. Their expansion efforts are expected to boost revenues, particularly from the Lote Maharashtra Industrial Development Corporation and Ambernath facilities, with contributions starting January-February 2026, Wagh said in a statement to the press.

Supriya Lifescience plans to launch 3-4 new products annually and is eyeing significant partnerships in contract manufacturing. A capex of Rs 160 crore is allocated for the Ambernath facility and Rs 350 crore for the Patalganga unit, funded through internal accruals. Positioning itself as a niche player in complex APIs, the company strengthens its presence in specialty markets amidst global industry instability.